Jacqueline Zummo

CIK: 0001798929

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (33.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (22.2%)

Compensation grants

Other (G, F, J, C, D, …)4 (44.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TARA

Protara Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (9 total)

TARA
Protara Therapeutics, Inc.
Apr 8, 2026
Sale(S)
Direct
1.1K shares at avg. $5.40$6K
TARA
Protara Therapeutics, Inc.
Apr 1, 2026
Sale(S)
Direct
22.6K shares at avg. $5.26$119K
TARA
Protara Therapeutics, Inc.
Jan 26, 2026
Tax Payment(F)
Direct
3.7K shares at avg. $6.67$25K
TARA
Protara Therapeutics, Inc.
Jan 20, 2026
Tax Payment(F)
Direct
6.6K shares at avg. $5.60$37K
TARA
Protara Therapeutics, Inc.
Jan 16, 2026
Award(A)
Direct
30K shares-
TARA
Protara Therapeutics, Inc.
Mar 26, 2025
Sale(S)
Direct
21.2K shares at avg. $4.53$96K
TARA
Protara Therapeutics, Inc.
Jan 24, 2025
Award(A)
Direct
24.5K shares-
TARA
Protara Therapeutics, Inc.
Jan 21, 2025
Tax Payment(F)
Direct
6.6K shares at avg. $4.76$31K
TARA
Protara Therapeutics, Inc.
Jan 3, 2025
Tax Payment(F)
Direct
2.2K shares at avg. $6.14$13K

		Type	Shares	Price		Ownership
Apr 8, 2026	TARA Protara Therapeutics, Inc.	Sale(S)	1,134	$5.40	$6,124	Direct
Apr 1, 2026	TARA Protara Therapeutics, Inc.	Sale(S)	22,598	$5.26	$118,865	Direct
Jan 26, 2026	TARA Protara Therapeutics, Inc.	Tax Payment(F)	3,724	$6.67	$24,839	Direct
Jan 20, 2026	TARA Protara Therapeutics, Inc.	Tax Payment(F)	6,578	$5.60	$36,837	Direct
Jan 16, 2026	TARA Protara Therapeutics, Inc.	Award(A)	30,000	-	$0	Direct
Mar 26, 2025	TARA Protara Therapeutics, Inc.	Sale(S)	21,224	$4.53	$96,145	Direct
Jan 24, 2025	TARA Protara Therapeutics, Inc.	Award(A)	24,500	-	$0	Direct
Jan 21, 2025	TARA Protara Therapeutics, Inc.	Tax Payment(F)	6,554	$4.76	$31,197	Direct
Jan 3, 2025	TARA Protara Therapeutics, Inc.	Tax Payment(F)	2,157	$6.14	$13,244	Direct

1-9 of 9 transactions

About Zummo Jacqueline

Zummo Jacqueline (SEC CIK 0001798929) files insider reports with the SEC as Chief R&D Officer of Protara Therapeutics, Inc. (TARA).

Signal8 holds 10 ownership filings by Zummo Jacqueline, all Form 4s, filed between Jan 7, 2025 and Apr 9, 2026. Those filings report 9 transactions, from Jan 3, 2025 to Apr 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zummo Jacqueline's filings is in NEW YORK, NY.

Recent filings by Zummo Jacqueline

Apr 8, 2026: Open-market sale of TARA shares (Form 4, code S).
Apr 1, 2026: Open-market sale of TARA shares (Form 4, code S).
Jan 26, 2026: Tax withholding of TARA shares (Form 4, code F).
Jan 20, 2026: Tax withholding of TARA shares (Form 4, code F).
Jan 16, 2026: Grant or award of TARA shares (Form 4, code A).

Other insiders filing for Protara Therapeutics, Inc. (TARA)

Shefferman Jesse, CEO and President
Levy Richard S, Director
Solomon Michael Edward, Director
Smith Cynthia, Director
SARGEN GREGORY, Director
Huang Jane, Director

How to read Form 4 transaction codes